Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could tailor leukemia drug dosing

NCT ID NCT06030089

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study looked at 20 adults with acute myeloid leukemia (AML) who were not healthy enough for strong chemotherapy. They received a standard combination of azacitidine and venetoclax. Researchers measured venetoclax levels in the blood at several time points to see if those levels relate to how well the drug works and how toxic it is. The goal is to gather information that could lead to personalized dosing in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
venetoclax and azacitidine
What this could lead to
If successful, this could help doctors personalize venetoclax dosing for AML patients, potentially improving treatment effectiveness and reducing side effects.
What could go wrong
This is a very small pilot study with only 20 participants, so results may not apply to everyone. It is designed to gather information, not to prove a new treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

  • CHU de Nice

    Nice, France

  • Hopital la Conception

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.